LMN-201

About Lumen Bioscience

Lumen Bioscience is pioneering a disruptive platform for oral biologic drugs using engineered spirulina, which promises faster, cheaper, and more scalable development compared to traditional cell-culture methods. The company's lead program, LMN-801, is a Phase 2 oral hormone therapy for weight loss, with additional Phase 2/3 programs targeting C. difficile infection and oxalate malabsorption. Backed by $185 million in investment and a robust patent portfolio, Lumen aims to address large, underserved markets by making biologic therapies more accessible and affordable.

Therapeutic Areas